Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling - Wikidata - awgldk - TriplyDB

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

http://www.wikidata.org/entity/Q28272891

about

B cell activation involves nanoscale receptor reorganizations and inside-out signaling by Syk The Homophilic Domain - An Immunological Archetype TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)New strategies in chronic lymphocytic leukemia: shifting treatment paradigms Targeting the B-cell receptor signaling pathway in B lymphoid malignancies The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292 Idelalisib for the treatment of chronic lymphocytic leukemia The pathogenesis of chronic lymphocytic leukemia Signal transduction in the chronic leukemias: implications for targeted therapies Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors Secondary mutations as mediators of resistance to targeted therapy in leukemia B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells The European Hematology Association Roadmap for European Hematology Research: a consensus document The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.AID-induced remodeling of immunoglobulin genes and B cell fate.Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells.Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project The long elusive IgM Fc receptor, FcμR.B-cell receptor signaling as a driver of lymphoma development and evolution.Silenced B-cell receptor response to autoantigen in a poor-prognostic subset of chronic lymphocytic leukemia.IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells Peptides that bind specifically to an antibody from a chronic lymphocytic leukemia clone expressing unmutated immunoglobulin variable region genes.Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.Antibody repertoire diversification through VH gene replacement in mice cloned from an IgA plasma cell.Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells Shifting ecologies of malignant and nonmalignant cells following BRAF inhibition.BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.

P2860

Q24299839-AD35A166-1E25-4399-AA0E-6E7D20AE36FF Q26752282-3BB3CEBE-93F3-41C1-84A8-95C8C0940EFC Q26773053-719B6200-8312-4C7B-975A-0F8E1B433091 Q26775506-E96EECFD-3279-4F2D-9E8E-0C4262C94500 Q26782633-F97459FC-275B-462C-8DB6-F4692BA34F34 Q26828496-9329E37F-30EC-4689-9941-114167369F68 Q26828782-4352C686-AE45-4F49-9CDE-06EBB6F22F0C Q26865760-0185B5BF-2B08-40F2-9DB8-8734AEBB4F9F Q26991890-79AB0E71-512B-4776-A3F7-93C946E5084F Q26995113-5A7ACC3C-4B28-4CCC-A614-63DAFEE183C0 Q27009550-D06AE84B-CFD4-444F-A089-E2BB126E0106 Q27015826-EF837F46-9248-4C65-B86F-CF4774477006 Q27025715-FC979D1E-7C74-45B3-BABF-A38AF83B8B9B Q27026031-4C546D6C-7166-40BA-A0C5-FF5662BC9D16 Q28081162-5496BBA2-A1CD-4B4C-8CB6-57AE94CFAF92 Q28087213-3E141C4F-ADBE-4E12-984F-2BB6E2B26C8E Q28245018-9D000564-DA9A-4135-93C0-CC7AB05CAC1D Q28830861-8F6F4A76-8B61-476E-B887-CF7F3FD685D3 Q30243968-E7633690-7B31-4520-A569-497276AFF322 Q30252869-093E747C-1FF3-4856-9924-78DD9406CB70 Q33576896-D0ACA788-5540-4958-B952-912EC5B09D30 Q33714712-489099CC-0671-4C46-8ADC-B230633BEBCB Q33749658-828DA53B-6EF2-410B-8141-FFF02389F816 Q33804706-913D902C-42CE-4018-A9D8-2FCD68FFDF60 Q33860644-D144BD42-17EE-442E-8270-BF9B8953A79D Q34020276-E5A7D77E-349C-4D5A-9E9B-F1C6E2F99962 Q34039406-CC796D0A-7DD1-42B9-8818-1216116C87C9 Q34041311-87E577FA-D993-4DFA-B91D-4141FEE8947E Q34137880-9B614E79-B0EA-4CE1-8E76-0DEE6836B89E Q34159967-73667F90-C566-4C3C-AD52-E7B57C553093 Q34398579-F73D5F15-EF6C-4968-A3A1-C3CED8C8E6E3 Q34463658-A47FFC82-E32A-4F23-A33F-83196A9474F5 Q34804388-72FE70AF-9627-4299-AB27-33025F5623AB Q34876742-7DC5EB5B-088A-40C5-AE27-017B5D43EA33 Q34901206-A3CA6D6A-DD9E-4FA8-B7F8-BF6DF13F736B Q35054626-2C92F1DC-1F9E-451F-BDB1-5F9131785DEC Q35062741-2AEF059F-8D6F-4DF9-BAF9-DC12E0E25EC7 Q35110849-DC00EB10-1450-48E7-93E7-BD0EBC7F6A20 Q35140015-03D1A42B-8A1F-40A5-B645-FD3579D01CBB Q35140116-3FA2459D-9372-40EF-AFD6-DEC6F37CBD8E

P2860

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

http://www.wikidata.org/entity/Q28272891

description

2012 nî lūn-bûn

@nan

2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

@ast

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

@en

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

@nl

type

label

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

@ast

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

@en

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

@nl

prefLabel

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

@ast

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

@en

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

@nl

P1433

Q28272891-0747338B-6A15-44D6-9047-B17781587BC2

P1476

Q28272891-F571413A-8282-400D-BFF9-A5BE3BC02022

P2093

Q28272891-32F125B4-9E29-4E67-A2F8-CD8E1EB05341

Q28272891-56C03DFA-B06E-41E3-9B95-1FE2CD1AB404

Q28272891-586CAE36-0F1E-48E9-B4AD-957984577DA3

Q28272891-66CB0605-9F61-4059-B760-24B3F12527F4

Q28272891-70AECAA9-EA0D-4641-AAAD-1E5ACCE9083C

Q28272891-84BABC99-EA3D-4034-BDA3-9B83797B55FD

Q28272891-8F41D49B-4E56-4E5F-9048-3CDCBA4C275F

Q28272891-9BBEAB13-47F3-45D3-BF35-CEC0CD25B7BD

Q28272891-9E1ABEFF-4645-446E-AEDF-E492C94EBC2A

Q28272891-CA86EFC6-A8C9-4306-A00C-B4A78EE831BE

P2860

Q28272891-45301497-45C2-4059-B80D-473E5564CE81

Q28272891-96A45838-ADAB-43C1-B96B-844C58642AF6

Q28272891-DEC74E79-DF3D-48C2-98E4-2B0DE88651AC

P2888

Q28272891-C2B56D34-8FC0-4693-A14C-4139536BEF4B

P304

Q28272891-8E30D020-5F40-4439-994B-F3E0812C8B40

P31

Q28272891-2928A7FF-6D99-4277-AA1C-788C6D0D70AB

P3181

Q28272891-03C432D8-A060-469C-9828-47658459E192

P356

Q28272891-CBFB25AE-CDEC-4DFD-BF6E-AFF9DFB90276

P407

Q28272891-D4302FBB-85D5-4E45-B3CC-37CB0006F59C

P433

Q28272891-001DB797-7441-47F6-B8CB-5A50D3122311

P478

Q28272891-EA10845A-B64E-480B-B679-BBC637A2C436

P50

Q28272891-ED809A66-EAE7-4057-A464-344663C56A07

Q28272891-F9D9A8CD-1C2C-4246-9A2A-66BF629355FE

P577

Q28272891-725C5DCF-02C7-4C27-A0B0-B18B20BDED33

P5875

Q28272891-0654B960-2A63-47FA-A5B3-21F9D8B716D2

P6179

Q28272891-1716E13C-8E41-4825-9619-B5BA8167473A

P698

Q28272891-BC450CBA-7F10-446F-9568-C9470102F02F

P921

Q28272891-5AF84EB6-1D0B-4286-B19B-A44A943F6C30

Q28272891-BC37C874-0FE6-42E0-9974-463A892C44A9

P3181

P356

P1433

P1476

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

@en

P2093

Daniel Hofmann

http://www.w3.org/2001/XMLSchema#string

Dunja Schneider

http://www.w3.org/2001/XMLSchema#string

Elena Surova

http://www.w3.org/2001/XMLSchema#string

Fabian Köhler

http://www.w3.org/2001/XMLSchema#string

Hassan Jumaa

http://www.w3.org/2001/XMLSchema#string

Hedda Wardemann

http://www.w3.org/2001/XMLSchema#string

Katja Zirlik

http://www.w3.org/2001/XMLSchema#string

Maike Buchner

http://www.w3.org/2001/XMLSchema#string

Marcus Dühren-von Minden

http://www.w3.org/2001/XMLSchema#string

Martina P Bach

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

Predominant autoantibody production by early human B cell precursors

P2888

P304

309-12

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3971611

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE11309

http://www.w3.org/2001/XMLSchema#string

P407

P433

7415

http://www.w3.org/2001/XMLSchema#string

P478

489

http://www.w3.org/2001/XMLSchema#string

P50

Hendrik Veelken

P577

2012-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230656806

http://www.w3.org/2001/XMLSchema#string

P6179

1000301913

http://www.w3.org/2001/XMLSchema#string

P698

22885698

http://www.w3.org/2001/XMLSchema#string

P921